Evidence map›Paper›PMID 42142270›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Jinjin Jiang, Bin Li, Jingfang Mao, Jiangang Zhang, Zili Li, Shaoli Song, Jingyi Cheng, Haiquan Chen

Abstract readComparative StudyValidation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinjin Jiang *Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 4365 Kangxin Road, Shanghai, 201321, China.
Bin Li *Department of Oncology, Medical College, Fudan University, Shanghai, China.
Jingfang Mao *Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Jiangang ZhangDepartment of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 4365 Kangxin Road, Shanghai, 201321, China.
Zili LiDepartment of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 4365 Kangxin Road, Shanghai, 201321, China.
Shaoli SongDepartment of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 4365 Kangxin Road, Shanghai, 201321, China. shaoli-song@163.com.
Jingyi ChengDepartment of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, 4365 Kangxin Road, Shanghai, 201321, China. fudansphic-nm@outlook.com.
Haiquan ChenDepartment of Oncology, Medical College, Fudan University, Shanghai, China. haiquanchen1@126.com.

Funding

Pudong New area science and technology development foundation PKJ2025-Y49
6 · The paper itself

Abstract

purposeAccurate lymph node staging in lung cancer remains challenging. This study evaluates the diagnostic efficacy of fibroblast activation protein inhibitor (FAPI) versus fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) using histopathology as the reference standard.

methodsThirty-two lung cancer patients with FDG-positive lymph nodes underwent [¹⁸F]F-FAPI PET/CT. Pathological confirmation of 71 lymph nodes (23 metastatic, 48 benign) was obtained via surgery or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Diagnostic efficacy was evaluated on both lymph node-based and patient-based, including maximum standardized uptake value (SUV

resultsMetastatic lymph nodes showed significantly higher FAPI uptake vs. benign lymph nodes [SUV

conclusion[

Indexed as

Fluorodeoxyglucose F18GelatinasesLung NeoplasmsMembrane ProteinsPositron Emission Tomography Computed TomographyAgedEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm StagingSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein AlphaFluorodeoxyglucose F18GelatinasesMembrane ProteinsSerine Endopeptidases[18F]F-FAPI PET/CTDiagnostic accuracyLung cancerLymph node metastasis

Identifiers

PMID42142270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.